Immunisation: Winter 2023-24

Baroness Altmann Excerpts

Wednesday 22nd February 2023 Lords Chamber

[Lord Evans of Rainow (Con)]

RSV has been a challenge for the science community for decades. Up until very recently, we have had only one, very expensive preventive measure. The noble Baroness talks about the workforce. It is very important that we have the talented NHS staff to deal with these issues. We have made significant scientific advances recently, and I will report back to the noble Baroness when I have some data on that.

[Baroness Altmann (Con)]

My Lords, following the question from the noble Baroness, Lady Bull, can my noble friend tell me what the department is doing on the rollout of convalescent plasma treatments for immunosuppressed patients, given that the monoclonal antibody Evusheld has now been rejected by both the US and NICE? If he cannot respond today, might he be willing to meet us both to discuss trials that might be ongoing for convalescent plasma with fractionated blood?

[Lord Evans of Rainow (Con)]

I am very happy to meet the noble Baroness and my noble friend.